Overview of Upcoming Investor Conferences
Aura Biosciences, Inc. (NASDAQ: AURA), a prominent clinical-stage biotechnology company spearheading advancements in precision therapies for solid tumors, is preparing to engage with investors at significant upcoming conferences. These events will give the CEO, Elisabet de los Pinos, PhD, an opportunity to share insights into the company’s vision and progress in developing treatments designed to preserve organ function.
Participation Details at Key Conferences
The first of these events is the TD Cowen 45th Annual Health Care Conference, where Dr. de los Pinos will partake in a fireside chat scheduled for March 4. This engaging session is set to start at 9:10 a.m. ET, allowing attendees to gain an understanding of the company’s strategic direction and innovations in the field of oncology.
Next, Aura Biosciences will also participate in the Leerink Partners Global Healthcare Conference on March 11, where another fireside chat is scheduled at 8:00 a.m. ET. This conference serves as a key platform for the company to address healthcare's evolving landscape and showcase its role in tackling solid tumors.
How to Access the Webcasts
For those unable to attend the live conferences, Aura Biosciences will provide a webcast of both events accessible through the “Investors & Media” section on the company's official website. These presentations will not only be live-streamed but will also be archived for 90 days, offering ample time for review and insights.
About Aura Biosciences and Its Innovations
Aura Biosciences is dedicated to developing groundbreaking precision therapies aimed at treating solid tumors while prioritizing the preservation of critical organ functions. The company’s lead candidate, AU-011, is making strides in late-stage development specifically for primary choroidal melanoma and shows promise in early-stage trials for other ocular oncological indications and bladder cancer.
The overarching mission of Aura Biosciences is to establish itself as an innovative leader in the global oncology field, fundamentally transforming the lives of patients through advanced therapies. Headquartered in Boston, the company is at the forefront of pushing the boundaries of cancer treatment.
Connecting with Aura Biosciences
For those seeking further information on Aura Biosciences, their initiatives, or insights from their leadership, you can visit their website at aurabiosciences.com. Stay updated on their latest news and advancements by following them on social media platforms, including X (formerly Twitter) at @AuraBiosciences, and connect via LinkedIn for professional updates.
Investor Relations and Queries
The released information is crucial for investors interested in the dynamic biotechnology sector and growth opportunities presented by Aura Biosciences. Questions or requests for further information can be directed to Alex Dasalla, the Head of Investor Relations and Corporate Communications, via email at IR@aurabiosciences.com.
Frequently Asked Questions
1. What is the focus of Aura Biosciences?
Aura Biosciences focuses on developing precision therapies for solid tumors while ensuring organ function is preserved.
2. When is Aura Biosciences participating in investor conferences?
Aura Biosciences will participate in two key investor conferences: The TD Cowen 45th Annual Health Care Conference on March 4 and the Leerink Partners Global Healthcare Conference on March 11.
3. How can I access the conference webinars?
The webcasts of the presentations will be available on the company’s website under the “Investors & Media” section and will be archived for future access.
4. What is the lead candidate in development by Aura Biosciences?
The lead candidate is AU-011, which is in late-stage development for primary choroidal melanoma and in early-stage development for various oncology indications.
5. How can I get in touch with the investor relations team?
You may contact Alex Dasalla via email at IR@aurabiosciences.com for any investor-related queries.
